Some studies have shown that an activating mutation in EGFR suppresses the expression of MHC-I in NSCLC through the extracellular signal-regulated kinase (ERK) kinase MEK pathway, which leads to the poor response of NSCLC to immunotherapy. Here, MAP2K7 is linked to non-small cell lung carcinoma.